Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis (2024) Vitali F, Rath T, Klenske E, Vögele AL, Ganzleben I, Zundler S, Strobel D, et al. Journal article Vedolizumab blocks alpha 4 beta 7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis (2022) Besendorf L, Müller T, Geppert CI, Schneider I, Mühl L, Atreya I, Vitali F, et al. Journal article α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis (2021) Melde M, Müller T, Schneider IHF, Geppert CI, Mühl L, Besendorf L, Allner C, et al. Journal article Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn’s disease patient upon infliximab-induced lupus-like syndrome (2021) Hirschmann S, Fischer S, Klenske E, Dechant K, Distler J, Treutlein C, Neurath M, Atreya R Journal article Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab (2021) Fischer S, Cohnen S, Klenske E, Schmitt H, Vitali F, Hirschmann S, Ramming A, et al. Journal article Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis (2020) Ganzleben I, Geppert CI, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, et al. Journal article Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch? (2020) Leclercq P, Jadot V, Bours V, Oliveira C, Neumann H, Bisschops R Journal article Targeting mucosal healing in Crohn’s disease: what the clinician needs to know (2019) Klenske E, Bojarski C, Waldner M, Rath T, Neurath M, Atreya R Journal article, Review article Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges (2017) Vetter M, Neurath M Journal article